What Fluarix Tetra Treats: Main Uses and Benefits

This immunization is used for active, pre-emptive protection against the illness known as seasonal influenza, which is commonly associated with acute systemic distress symptoms. This vaccine is commonly used to help with prevention of disease caused by Influenza A subtype viruses (H1N1 and H3N2) and Type B viruses (two lineages) contained in the annual formulation.

This prophylactic use is applied across the therapeutic domain of infectious disease prevention and is relevant for managing symptoms that interfere with daily comfort, such as sudden high fever, profound fatigue, and severe muscle aches. This use is applied across domains where additional symptomatic support is needed to mitigate the potential for severe health outcomes. It is considered relevant for older adults and persons in other high-risk patient groups who seek prophylactic protection.

This commonly used approach assists with maintaining functional stability when symptoms become more noticeable during the flu season and contributes to easing the overall symptom load.

Quick Fact: Relief for Acute Systemic Distress (This supports easing symptoms related to systemic imbalance and heightened physiological activity, such as high fever and body malaise.)

Regulatory References

1. NIH DailyMed Label for Fluarix

Fluarix Tetra is an inactivated quadrivalent influenza vaccine indicated for active immunization to prevent influenza disease caused by the two influenza A subtypes and two influenza B types contained in the vaccine.

Who Can Use Fluarix Tetra?

This vaccine is approved for use in individuals who are 6 months of age and older. Annual vaccination is generally recommended for all people in this age group who do not have a specific contraindication.

Age Group	Indication
Children	6 months and older
Adolescents and Adults	All ages

Who Cannot Use Fluarix Tetra?

Fluarix Tetra is contraindicated for anyone with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous dose of any influenza vaccine. Patients with a moderate or severe acute illness, with or without a fever, should typically postpone vaccination until they have recovered.

In cases where Guillain-Barré syndrome (GBS) has occurred within six weeks of a prior influenza vaccination, the decision to administer Fluarix Tetra should be made by a healthcare provider after carefully considering the potential benefits and risks.

Interactions with other medicines and products — official regulatory information for Fluarix Tetra

Interaction Scope

Property	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Immunosuppressive agents, Other injectable vaccines, and Anticoagulant therapy.
Specific interacting medicines (if explicitly listed)	The label cites immunosuppressive therapy as a class; specific co-administered vaccines mentioned in context include pneumococcal polysaccharide vaccines and adjuvanted herpes zoster vaccine.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic: Interference with the patient's intended immune response. Physical/Procedural: Constraints on the site of co-administration. No pharmacokinetic interactions (CYP or transporter-mediated) are officially documented.
Timing-based interaction rules (if applicable)	Other Injectable Vaccines: If administered concomitantly, the vaccines should always be administered at different injection sites [FDA Label / HPRA SmPC].
Population-specific interaction notes (if applicable)	Individuals with Thrombocytopenia or Coagulation Disorders (e.g., on anticoagulant therapy): Caution is required during intramuscular administration due to the documented risk of haematoma following injection [FDA Label].
Interaction-related restrictions	Must not be administered concomitantly with other injectable vaccines in the same injection site.

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation Statement
Interaction severity classification (as defined in official documents)	Altered Immunocompetence: May result in a lower immune response (functional impact on efficacy). Physical: Caution required in individuals with bleeding disorders due to administration route.
Regulatory basis (EMA / FDA / etc.)	United States FDA Prescribing Information (Altered Immunocompetence), HPRA Summary of Product Characteristics (Timing/Site and Serological Interference).
Interaction-context constraints (as defined in official documents)	Serological Test Interference: Following administration, false positive results have been observed in serology tests (ELISA method) for antibodies against HIV1, Hepatitis C, and especially HTLV1 [HPRA SmPC].

Resulting Interaction Structure

Official interaction statements:

• Co-administration with immunosuppressive therapy may lead to a lower immune response compared to the response observed in immunocompetent persons.
• If co-administered with another injectable vaccine, both vaccines should always be administered at different injection sites.
• Caution is required for intramuscular administration in individuals with thrombocytopenia or any coagulation disorder due to the officially documented risk of haematoma following injection.
• Influenza vaccination has been associated with false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C, and HTLV1; the regulatory text notes the Western Blot technique disproves these findings.

The regulatory documents define the product's interaction structure primarily through pharmacodynamic interference with the intended immune response and procedural constraints governing co-administration with other injections. There are no documented pharmacokinetic (CYP or transporter-mediated) interactions listed in the official labels. The profile also includes a formal caution regarding the physical risks of injection in persons with pre-existing coagulation disorders and notes potential interference with specific laboratory tests.

Fluarix Tetra, an inactivated split-virion influenza vaccine, introduces structural antigens—specifically the hemagglutinin proteins—derived from two influenza A virus subtypes and two influenza B virus types. Following intramuscular administration, the quadrilvalent antigen mixture interacts with host antigen-presenting cells (APCs) in the local tissue environment.

APCs internalize the viral components and process them into epitopes for presentation on Major Histocompatibility Complex (MHC) class I and II molecules. This molecular presentation functions as an agonist signal, activating T-helper( CD4^+) and cytotoxic( CD8^+) T lymphocytes, initiating the cell-mediated immune response. Simultaneously, the exposed antigens stimulate B lymphocytes, driving their differentiation into plasma cells. These plasma cells commence the synthesis and secretion of antigen-specific immunoglobulins, primarily the IgG isotype, into systemic circulation. This systemic cascade results in the circulation of hemagglutination-inhibition( HI) antibodies, which are the biological target and functional interaction component of the humoral immune response.

How to use Fluarix Tetra

The administration of Fluarix Tetra involves specific parameters concerning its route, dose volume, and schedule.

Category	Instruction
Route of administration	The vaccine must be administered by intramuscular injection (IM) only. The product must not be administered intravenously, intradermally, or subcutaneously.
Dosing schedule	The standard dose volume for all approved ages (6 months and older) is 0.5 mL per injection.
Preparation requirements	The pre-filled syringe requires shaking well immediately prior to use. The suspension must be visually inspected for particulate matter or discoloration, and must be discarded if either is observed.
Age-group administration rules	Ages 9 years and older receive one 0.5 mL dose annually. Children aged 6 months through 8 years who have not previously been vaccinated against influenza require a two-dose primary series (0.5 mL each), with doses separated by at least 4 weeks.
Special procedural conditions	The preferred injection site is the anterolateral thigh for children aged 6 through 11 months, and the deltoid muscle of the upper arm for persons aged 12 months and older. If administered simultaneously with other injectable vaccines, a separate injection site must be used for each product.

---

Instruction Classifications (High-Level)

Category	Classification
Administration method type	Parenteral / Intramuscular
Frequency pattern	Annual (seasonal) with a single-dose regimen for most; two-dose series in specific pediatric cases.

---

Connection to the overall use protocol:

The protocol involves a standardized, yearly use pattern delivered exclusively via the intramuscular route to the specified muscle groups. This ensures consistent delivery of the 0.5 mL dose across age groups, with the only primary variation being the two-dose requirement for the initial administration in certain younger children. These parameters define the procedural steps for its proper use.

Research evidence / Overview of Studies for Fluarix Tetra

Evidence for Preventing Seasonal Influenza Illness (Clinical Trials)

This section summarizes the official research that examined how Fluarix Tetra was evaluated in the key indication: research into the prevention of confirmed illness caused by the four specific influenza strains included in the vaccine. Research on this outcome was evaluated in both randomized controlled trials (RCTs) and real-world observational studies. The studies explored the occurrence of laboratory-confirmed influenza illness—an outcome related to systemic or functional imbalance—in people who received the vaccine compared to those who received a different influenza vaccine or, historically, a placebo. The findings describe patterns observed in the studies regarding the reported rates of confirmed illness.

Research Examining the Immune Response (Immunogenicity Studies)

Fluarix Tetra was also evaluated in studies focusing on the immune system's reaction. These studies are known as immunogenicity trials. This research focused on whether the vaccine was associated with the body's production of protective humoral antibodies against the four influenza strains. These studies monitored specific antibody levels in the blood, known as Geometric Mean Titers (GMTs), and the Seroconversion Rate (SCR). These antibody levels are considered surrogate measures; they help contextualize symptom patterns, but they are not a direct measure of preventing the illness itself. Studies explored the patterns of immune response from the quadrivalent formulation in comparison to licensed trivalent influenza vaccines.

Unanswered Questions and Research Gaps

Research provides context but not individual predictions. Data for certain specific high-risk groups—such as people who are severely immunosuppressed or those with specific underlying chronic conditions—are often inferred from broader evidence, and dedicated studies focused solely on these subgroups are less frequent in the current evidence base. Furthermore, the use of immunological measurements (GMTs and SCRs) as surrogate endpoints means that the clinical outcomes associated with these measures are still an area of exploration. Limited information is available for long-term outcomes, as the effects beyond a single influenza season are not fully established.

Key Studies & References

1. FLUARIX (Influenza Vaccine) - US Prescribing Information / Label (Citing NCT01439360 and NCT00383123 trials)
2. Quadrivalent Seasonal Influenza Vaccine (Split Virion, Inactivated) Southern Hemisphere 2023 Fluarix Tetra SH2023 Vaccine (Citing studies D-QIV-004, D-QIV-003, D-QIV-008, D-QIV-010)
3. Immunogenicity, Efficacy, and Effectiveness of Influenza Vaccines - CDC Archive (Reviewing data on LCI, immunogenicity and two-dose schedules for children)

Common questions about Fluarix Tetra (FAQ)

Q: What is Fluarix Tetra and what is it used for?

A: Fluarix Tetra is a quadrivalent (four-component) influenza vaccine (split virion, inactivated) that is used for active immunization to prevent influenza disease caused by the two influenza A subtype viruses (H1N1 and H3N2) and the two influenza B type viruses contained in the vaccine. It is indicated for use in adults and children from 6 months of age.

---

Q: What is the recommended dosage and schedule for Fluarix Tetra?

A: Fluarix Tetra is typically administered as a single 0.5 mL injection.

For children 6 months to less than 9 years of age who have not previously been vaccinated against influenza, a second 0.5 mL dose is required after an interval of at least four weeks.

For persons 9 years of age and older, only a single 0.5 mL dose is required.

---

Q: Where is Fluarix Tetra administered?

A: Fluarix Tetra is administered by intramuscular injection. The preferred site for injection is the deltoid muscle of the upper arm for persons 12 months and older with adequate muscle mass. For children aged 6 through 11 months, the anterolateral thigh is the preferred site.

---

Q: What are the most common side effects of Fluarix Tetra?

A: The most common side effects vary by age group, but often include pain at the injection site, redness (erythema) or swelling at the injection site, headache, muscle aches (myalgia), and fatigue.

In adults, the most common solicited adverse reactions include injection site pain, myalgia, fatigue, and headache.

In children aged 6 through 35 months, common reactions may include irritability, loss of appetite, drowsiness, and pain and redness at the injection site.

In children aged 3 through 17 years, common reactions include pain, redness, and swelling at the injection site, as well as muscle aches, fatigue, and headache.

---

Q: Who should not receive Fluarix Tetra?

A: Fluarix Tetra should not be administered to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine.

---

Q: Can Fluarix Tetra be given to pregnant or breastfeeding women?

A: The vaccine is not expected to cause problems for breastfed babies. For pregnant women, a doctor will discuss the potential benefits and risks of vaccination.

How to Store and Dispose of Fluarix Tetra

The following requirements govern the storage, handling, and disposal of Fluarix Tetra, based on official regulatory labeling.

Storage Requirement	Details
Temperature Range	Store in a refrigerator between 2 C and 8 C (36 F and 46 F).
Freezing Prohibition	Do not freeze this vaccine, as freezing will destroy the product.
Light Protection	Store in the original packaging to protect the vaccine from light.
Handling Notes	Keep the vaccine out of the sight and reach of children and do not use the product after the stated expiry date.
Disposal Instructions	Do not dispose of this medicine via wastewater or household waste. Consult your pharmacist for instructions on how to properly discard the unused vaccine, which helps protect the environment.